Associate

Newsweek Web Series “Unconventional” Featuring Naveed Jamali Honored by 2024 Webby Awards

Retrieved on: 
Monday, April 8, 2024
Webby Awards, B-2, Associate, Large, Marine, International Academy, Internet, Digital art, Webby, B-52, Woman, Stealth, Newsweek, Convention (norm), IADAS

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The International Academy of Digital Arts & Sciences (IADAS) announced the nominations for the 28th Annual Webby Awards, recognizing the Newsweek web series Unconventional as an honoree for best-branded entertainment video series.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The International Academy of Digital Arts & Sciences (IADAS) announced the nominations for the 28th Annual Webby Awards, recognizing the Newsweek web series Unconventional as an honoree for best-branded entertainment video series.
  • The series features Newsweek Editor at Large, Naveed Jamali, who is a military expert, author, veteran, journalist, and former spy.
  • For each episode, Naveed embeds for 36 hours with various military commands, giving an inside look at today's armed forces in action.
  • This year’s Webby Award winners will be announced on May 13, 2024 at Cipriani Wall Street in Manhattan.

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Retrieved on: 
Monday, April 8, 2024
Surgeon, Plastic, Associate, Education, Matrix, National Cancer Institute, Bellevue Hospital, MD Anderson Cancer Center, NYU, University, General surgery, Surgical oncology, Health, FACS, Dentistry

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

Key Points: 
  • MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.
  • Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems.
  • “With more than 30 years of experience in plastic and reconstructive surgery, I understand the needs and challenges in this space,” said Dr. Langstein.
  • "We are thrilled to welcome Dr. Langstein to our team," said Paul Talmo, Chief Technology Officer of TELA Bio.

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Retrieved on: 
Friday, April 5, 2024
BCG, Bacillus, Associate, Patient, Mayo Clinic, Data, Cancer, Enrollment, Therapy, CIS, Pharmaceutical industry

We look forward to sharing data from post-reinduction, six-month evaluable patients in our ADVANCED-2 trial in the second half of 2024,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.

Key Points: 
  • We look forward to sharing data from post-reinduction, six-month evaluable patients in our ADVANCED-2 trial in the second half of 2024,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
  • Data reported today highlight the potential of TARA-002 in patients with NMIBC.
  • Data were derived from three-month evaluable NMIBC patients with CIS pooled across the Company’s ADVANCED-1 Phase 1a, Phase 1b-expansion and ADVANCED-2 Phase 2 trials of TARA-002 in patients with high-risk NMIBC, including BCG-Unresponsive, BCG-Experienced and BCG-Naïve patients.
  • The Company plans to explore additional dosing cohorts, which may prove effective in patients who might benefit.

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Retrieved on: 
Thursday, April 4, 2024
Disease, MSSA, MRSA, Development, TARGET, Associate, Partnership, CABP, New Drug Application, Patient, HHS, Mortality, NDA, Fungal infection, Staphylococcus aureus, Bronchopneumonia, Infection, Safety, SAB, ASPR, Staphylococcus, Ceftobiprole, Administration, FDA, ABSSSI, Pharmaceutical industry

David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.

Key Points: 
  • David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.
  • The positive decision by the FDA is a key milestone towards bringing ZEVTERA to patients in the US.
  • This approval is a landmark for ceftobiprole and reflects its broad clinical utility.
  • Through this partnership, Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work.

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Retrieved on: 
Thursday, April 4, 2024
B-cell lymphoma, Toxicity, Associate, Part, Patient, CRS, University, Doctor of Philosophy, Therapy, Diffuse large B-cell lymphoma, Infrared spectroscopy correlation table, Division, ADC, Hematology, Cytokine release syndrome, Lymphoma, Follicular lymphoma, Pharmaceutical industry

LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Key Points: 
  • Additionally, after the first investigator assessment, evidence of anti-tumor activity was observed among the majority of patients, with mixed histologies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL).
  • “The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • For more information about the LOTIS-7 trial, visit clinicaltrials.gov (NCT04970901).

Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

Retrieved on: 
Wednesday, April 3, 2024
Cardiorenal syndrome, Congestion, DSR, Brussels Stock Exchange, Liver disease, Associate, RED, Patient, NYHA, Mortality, Cancer, Fluid, Heart failure, European Journal, Diuretic, Overload, Syndrome, Yale University, Pharmaceutical industry

The publication can be accessed here .

Key Points: 
  • The publication can be accessed here .
  • Dr. Jeffrey Testani, Associate professor at Yale University and senior author of the publication commented: “Cardiorenal syndrome is a major clinical challenge in heart failure with a clear unmet need for therapies to effectively and durably address congestion and cardio-renal dysfunction.
  • Currently the mainstay of therapy for sodium avidity and congestion are the loop diuretics, which actually worsen sodium avidity and cardiorenal syndrome.
  • Diuretic-resistant heart failure and cardiorneal syndrome are large and growing markets both in the US and rest of world, with the clear need for novel treatments that can improve clinical outcomes beyond loop diuretics.

Enhancing Positive Emotions to Prevent Depression in Youth - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, April 2, 2024
Depression, Emotion, Vanderbilt University, Mood, Associate, Risk, Research, Neuroscience, Brain, Psychology, Happiness, CDC, Suicide, Sadness

The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.

Key Points: 
  • The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds will be the webinar host.
  • Register today at BBRFoundation.org
    Treatment for depression traditionally focuses on reducing negative emotions like sadness or anger and less on increasing positive emotions like contentment and happiness.
  • In this talk, Dr. Kujawa will first review research informed by neuroscience that highlights difficulties with positive emotions as a key risk factor for the development of depression in youth.

Hexiris Welcomes Dr. Paul Harasymowycz to Its Scientific Committee

Retrieved on: 
Tuesday, April 2, 2024
McGill University, Glaucoma, Health, Pressure, CUO, Disease, Associate, Risk, Patient, Knowledge, Research, MD, Slit lamp, Ophthalmology, Publication, Medical director, FDA, Glaucoma surgery, Medical device

DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.
  • “We are proud that Dr. Harasymowycz has agreed to join our scientific committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris.
  • Over the past 20 years, Dr. Harasymowycz has distinguished himself through his extensive research and more than 90 publications in national and international scientific journals, and book chapters on glaucoma.
  • As a result, the Hexiris MIGS Solution is expected to generate considerable cost benefits for the health system.

SBA Recognizes 2024 Resource Partners of the Year

Retrieved on: 
Friday, March 29, 2024
SBA, Mississippi State University, Business education, The Business Council, Innovation, Raytheon Company, Woman, Central business district, Business Center (TV series), Associate, University, Army, Growth, National Small Business Week, Small business, Hope, Metro, Human

WASHINGTON, March 29, 2024 (GLOBE NEWSWIRE) -- Today, Administrator Isabel Casillas Guzman , head of the U.S. Small Business Administration (SBA) and the voice in President Biden’s Cabinet for America’s more than 33 million small businesses, recognized four SBA Resource Partners of the Year awardees.

Key Points: 
  • WASHINGTON, March 29, 2024 (GLOBE NEWSWIRE) -- Today, Administrator Isabel Casillas Guzman , head of the U.S. Small Business Administration (SBA) and the voice in President Biden’s Cabinet for America’s more than 33 million small businesses, recognized four SBA Resource Partners of the Year awardees.
  • "As our small business owners across America continue to exhibit resilience and hope, our SBA Resource Partner network leverages the power of SBA tools and resources."
  • SCORE National Chapter of the Year:
    SCORE Southeast Wisconsin – Milwaukee, Wisconsin
    SCORE, an SBA resource partner, named SCORE Southeast Wisconsin the 2024 Chapter of the Year for its outstanding support of small businesses.
  • Under Shawntay’s leadership, the Great Lakes Women’s Business Council has been recognized by the Association of Women’s Business Centers, a national SBA resource partner.

Afghan Women’s Rights Leader, Shabana Basij-Rasikh, to Deliver Roger Williams University Commencement Address

Retrieved on: 
Wednesday, March 27, 2024
Women's rights, Speech, Science, Associate, Perseverance, Risk, District court, Trustee, Education, Environmental science, Research, Graduation, Basij, Faculty, Roger Williams University, Diplomacy, Student, Woman, Empowerment, Radio, Taliban, Supreme court, RWU, State, School, Nursing

During her visit to Roger Williams University in 2021, Basij-Rasikh spoke about women’s rights and access to girls’ education in Afghanistan.

Key Points: 
  • During her visit to Roger Williams University in 2021, Basij-Rasikh spoke about women’s rights and access to girls’ education in Afghanistan.
  • COMMENCEMENT DATE: The university-wide Commencement celebration for undergraduate, graduate and law students of the Class of 2024 will be held on Friday, May 17.
  • LIVESTREAM: RWU will provide a livestream enabled for broadcast and radio recording of the main university ceremony.
  • PHOTO CAPTION: Shabana Basij-Rasikh, founder of the School of Leadership Afghanistan (SOLA), will deliver the keynote speech and receive an honorary degree at the RWU Commencement ceremony on Friday, May 17.